多发性骨髓瘤试验中微小残留病评估实施与报告的国际统一化
多发性骨髓瘤(MM)临床试验中微小残留病(MRD)评估的实施与报告存在显著异质性,影响数据解读和后续研究设计。国际专家组召开会议,就哪些MM试验应纳入MRD、推荐评估时间点、MRD检测方法预期分析验证、按意向治疗原则报告MRD结果、以及纳入新型外周血和影像学残留病检测方法等达成共识,并以13条共识声明总结推荐,供申办方、研究者、编辑和审稿人在设计、实施和解读MM试验时遵循。
要点
- 国际专家组就MM临床试验中MRD评估与报告达成共识,形成13条共识声明。
- 共识涵盖哪些MM试验应纳入MRD、推荐评估时间点及MRD检测方法的预期分析验证。
- MRD结果报告应遵循意向治疗原则,并纳入新型外周血和影像学检测方法。
核心结论
- 国际专家组就MM临床试验中MRD评估与报告达成共识,并以13条共识声明总结推荐,供申办方、研究者、编辑和审稿人在设计、实施和解读MM试验时遵循。
研究设计与样本
- 国际专家组召开会议,就MM临床试验中MRD评估与报告的统一化达成共识。
主要发现
- 临床试验间MRD评估与报告存在显著异质性,给数据解读和后续研究设计带来挑战。
- 专家组就哪些MM试验应纳入MRD、推荐MRD评估时间点及MRD检测方法预期分析验证达成共识。
- 专家组提出按意向治疗原则报告MRD结果的参数,并就纳入新型外周血和影像学残留病检测方法提供指导。
关键数值与推荐
- 共识以13条共识声明总结推荐。
- 共识涵盖哪些MM试验应纳入MRD、推荐MRD评估时间点及MRD检测方法预期分析验证。
- 共识提出按意向治疗原则报告MRD结果的参数。
- 共识就纳入新型外周血和影像学残留病检测方法提供指导。
临床怎么用
- 申办方、研究者、编辑和审稿人在设计、实施和解读MM试验时应遵循13条共识声明。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity across clinical trials in how MRD is assessed and reported, creating challenges for data interpretation and for the design of subsequent studies. We convened an international panel of MM investigators to harmonize how MRD should be assessed and reported in MM clinical trials. The panel provides consensus on which MM trials should include MRD, the recommended time points for MRD assessment, and expected analytical validation for MRD assays. We subsequently outlined parameters for reporting MRD results implementing the intention-to-treat principle. The panel provides guidance regarding the incorporation of newer peripheral blood-based and imaging-based approaches to detection of residual disease. Recommendations are summarized in 13 consensus statements that should be followed by sponsors, investigators, editors, and reviewers engaged in designing, performing, and interpreting MM trials.
引用
- Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2020. PMID: 32778736. doi:10.1038/s41375-020-01012-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。